Tuesday, 1 January 2013

Space travel may be harmful to the brain, study suggests; Prolonged cosmic radiation exposure could hasten Alzheimer's

Dec. 31, 2012 — As if space travel was not already filled with enough dangers, a new study out today in the journal PLOS ONE shows that cosmic radiation -- which would bombard astronauts on deep space missions to places like Mars -- could accelerate the onset of Alzheimer's disease.

"Galactic cosmic radiation poses a significant threat to future astronauts," said M. Kerry O'Banion, M.D., Ph.D., a professor in the University of Rochester Medical Center (URMC) Department of Neurobiology and Anatomy and the senior author of the study. "The possibility that radiation exposure in space may give rise to health problems such as cancer has long been recognized. However, this study shows for the first time that exposure to radiation levels equivalent to a mission to Mars could produce cognitive problems and speed up changes in the brain that are associated with Alzheimer's disease."

While space is full of radiation, the earth's magnetic field generally protects the planet and people in low earth orbit from these particles. However, once astronauts leave orbit, they are exposed to constant shower of various radioactive particles. With appropriate warning, astronauts can be shielded from dangerous radiation associated with solar flares. But there are also other forms of cosmic radiation that, for all intents and purposes, cannot be effectively blocked.

Because this radiation exists in low levels, the longer an astronaut is in deep space, the greater the exposure. This is a concern for NASA as the agency is planning manned missions to a distant asteroid in 2021 and to Mars in 2035. The round trip to the red planet, in particular, could take as long as three years.

For over 25 years, NASA has been funding research to determine the potential health risks of space travel in an effort to both develop countermeasures and determine whether or not the risks warranted sending men and women on extended missions in deep space.

Since that time, several studies have demonstrated the potential cancer, cardiovascular, and musculoskeletal impact of galactic cosmic radiation. The study out today for the first time examines the potential impact of space radiation on neurodegeneration, in particular, the biological processes in the brain that contribute to the development of Alzheimer's disease. O'Banion -- whose research focuses on how radiation affects the central nervous system -- and his team have been working with NASA for over eight years.

The researchers studied the impact of a particular form of radiation called high-mass, high-charged (HZE) particles. These particles -- which are propelled through space at very high speeds by the force of exploding stars -- come in many different forms. For this study the researcher chose iron particles. Unlikely hydrogen protons, which are produced by solar flares, the mass of HZE particles like iron, combined with their speed, enable them to penetrate solid objects such as the wall and protective shielding of a spacecraft.

"Because iron particles pack a bigger wallop it is extremely difficult from an engineering perspective to effectively shield against them," said O'Banion. "One would have to essentially wrap a spacecraft in a six-foot block of lead or concrete."

A portion of the research was conducted at the NASA Space Radiation Laboratory at Brookhaven National Laboratory on Long Island. NASA located its research operation at Brookhaven to take advantage of the Lab's particle accelerators which -- by colliding matter together at very high speeds -- can reproduce the radioactive particles found in space.

The researchers specifically wanted to examine whether or not radiation exposure had the potential to accelerate the biological and cognitive indicators of Alzheimer's disease, particularly in individuals who may be predisposed to developing the disease. To accomplish this they chose study the impact on animal models of Alzheimer's disease. These particular models have been extensively studied and scientists understand the precise timeframe in which the disease progresses over time.

At Brookhaven, the animals were exposed to various doses of radiation, including levels comparable to what astronauts would be experience during a mission to Mars. Back in Rochester, a team of researchers -- including URMC graduate student Jonathan Cherry, who was first author on the paper -- evaluated the cognitive and biological impact of the exposure. The mice underwent a series of experiments during which they had to recall objects or specific locations. The researchers observed that mice exposed to radiation were far more likely to fail these tasks -- suggesting neurological impairment -- earlier than these symptoms would typically appear.

The brains of the mice also showed signs of vascular alterations and a greater than normal accumulation of beta amyloid, the protein "plaque" that accumulates in the brain and is one of the hallmarks of the disease.

"These findings clearly suggest that exposure to radiation in space has the potential to accelerate the development of Alzheimer's disease," said O'Banion. "This is yet another factor that NASA, which is clearly concerned about the health risks to its astronauts, will need to take into account as it plans future missions."

Additional co-authors include Jacqueline Williams, Ph.D. and John Olschowka, Ph.D. with URMC and Bin Liu, Ph.D., Jeffrey Frost, and Cynthia Lemere, Ph.D. with Harvard Medical School. The study was funded by NASA.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Rochester Medical Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Jonathan D. Cherry, Bin Liu, Jeffrey L. Frost, Cynthia A. Lemere, Jacqueline P. Williams, John A. Olschowka, M. Kerry O’Banion. Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased Aß Plaque Accumulation in a Mouse Model of Alzheimer’s Disease. PLoS ONE, 2012; 7 (12): e53275 DOI: 10.1371/journal.pone.0053275

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Differences in generic pill characteristics may lead to interruptions in essential medication use

Dec. 31, 2012 — Generic medications currently account for over 70 percent of prescriptions dispensed. However, while generic drugs are clinically bioequivalent to the brand-name version, they often differ in their physical characteristics, such as color and shape. Researchers from Brigham and Women's Hospital (BWH) have found that some patients who receive generic drugs that vary in their color are over 50 percent more likely to stop taking the drug, leading to potentially important and potentially adverse clinical effects.

The study will be published online Dec. 31, 2012 in the Archives of Internal Medicine.

"Pill appearance has long been suspected to be linked to medication adherence, yet this is the first empirical analysis that we know of that directly links pills' physical characteristics to patients' adherence behavior," explained Aaron S. Kesselheim MD, JD, MPH, assistant professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH, and principal investigator of this study. "We found that changes in pill color significantly increase the odds that patients will stop taking their drugs as prescribed."

The researchers conducted a case-control study of patients taking antiepileptic drugs and compared the odds that patients who did not refill their medication had been given pills that differed in color or shape from the prior prescriptions. Using a large national database of filled prescriptions, when the researchers identified a break in the patient's use of the drug, they looked at the previous two prescription fillings to see if they were the same color and shape. They found that interruptions in the prescription filling occurred significantly more frequently when the pills had different color. Interruptions in antiepileptic drug use for even a few days can raise the risk of seizure and have important medical and social consequences for patients.

These findings offer important take-home messages for physicians, pharmacists, and patients. As Kesselheim explained, "Patients should be aware that their pills may change color and shape, but that even differently-appearing generic drugs are approved by the FDA as being bioequivalent to their brand-name counterparts and are safe to take. Physicians should be aware that changes in pill appearance might explain their patients' non-adherence. Finally, pharmacists should make a point to tell patients about the change in color and shape when they change generic suppliers."

Researchers acknowledge that medication adherence is a multi-faceted issue, but suggest that taking steps to permit (or even require) similarity in pill appearance among bioequivalent brand name and generic drugs may offer a relatively simple way to contribute to better adherence.

This research was supported by a career development award from the Agency for Healthcare Research & Quality (K08HS18465-01), and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. Dr. Choudhry has received unrestricted research grants from CVS Caremark, Aetna, the Commonwealth Fund, and the Robert Wood Johnson Foundation to study medication adherence. Dr. Shrank has received unrestricted research funding from CVS Caremark, Aetna, Teva, Lilly, and the National Association of Chain Drug Stores.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Brigham and Women's Hospital, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Kesselheim AS, Misono AS, Shrank WH, et al. Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence. Archives of Internal Medicine, 2012; DOI: 10.1001/2013.jamainternmed.997

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here